About Rigel Pharmaceuticals, Inc.
https://www.rigel.comRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
CEO
Raul R. Rodriguez
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-27 | Reverse | 1:10 |
| 2003-06-25 | Reverse | 1:9 |
ETFs Holding This Stock
Summary
Showing Top 3 of 108
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Jefferies
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Cantor Fitzgerald
Neutral
B. Riley Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:5M
Value:$195.6M
BLACKROCK FUND ADVISORS
Shares:4.38M
Value:$171.44M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:3.39M
Value:$132.68M
Summary
Showing Top 3 of 205
About Rigel Pharmaceuticals, Inc.
https://www.rigel.comRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $69.46M ▼ | $36.29M ▲ | $27.9M ▼ | 40.17% ▼ | $1.55 ▼ | $30.12M ▼ |
| Q2-2025 | $101.69M ▲ | $36.08M ▼ | $59.61M ▲ | 58.63% ▲ | $3.33 ▲ | $62.46M ▲ |
| Q1-2025 | $53.33M ▼ | $36.15M ▲ | $11.45M ▼ | 21.46% ▼ | $0.64 ▼ | $13.97M ▼ |
| Q4-2024 | $57.6M ▲ | $35.15M ▲ | $14.34M ▲ | 24.9% ▲ | $0.81 ▲ | $17.78M ▲ |
| Q3-2024 | $55.31M | $33.23M | $12.42M | 22.46% | $0.71 | $15.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $137.14M ▲ | $242.53M ▲ | $124.92M ▲ | $117.61M ▲ |
| Q2-2025 | $108.38M ▲ | $206.74M ▲ | $124.8M ▼ | $81.93M ▲ |
| Q1-2025 | $77.1M ▼ | $175.97M ▲ | $157.41M ▼ | $18.57M ▲ |
| Q4-2024 | $77.32M ▲ | $163.98M ▲ | $160.69M ▲ | $3.29M ▲ |
| Q3-2024 | $61.11M | $139.42M | $154.06M | $-14.64M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.9M ▼ | $24.03M ▼ | $-33.17M ▼ | $4.27M ▲ | $-4.87M ▼ | $24.02M ▼ |
| Q2-2025 | $59.61M ▲ | $30.54M ▲ | $-23.28M ▼ | $418K ▼ | $7.68M ▲ | $30.54M ▲ |
| Q1-2025 | $11.45M ▼ | $-893K ▼ | $-10.55M ▲ | $484K ▼ | $-10.96M ▼ | $-893K ▼ |
| Q4-2024 | $14.34M ▲ | $14.5M ▼ | $-10.91M ▼ | $1.47M ▲ | $5.05M ▼ | $14.48M ▼ |
| Q3-2024 | $12.42M | $21.68M | $3.8M | $-9.84M | $15.64M | $21.67M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Contract revenues from collaborations | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $40.00M ▲ |
 Discounts and allowances | $0 ▲ | $-20.00M ▼ | $-20.00M ▲ | $-20.00M ▲ |
 Gross product sales | $120.00M ▲ | $90.00M ▼ | $60.00M ▼ | $80.00M ▲ |
 Milestone | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product sales net | $80.00M ▲ | $60.00M ▼ | $40.00M ▼ | $60.00M ▲ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Raul R. Rodriguez
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-27 | Reverse | 1:10 |
| 2003-06-25 | Reverse | 1:9 |
ETFs Holding This Stock
Summary
Showing Top 3 of 108
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Jefferies
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Cantor Fitzgerald
Neutral
B. Riley Securities
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
OPPENHEIMERFUNDS, INC.
Shares:5M
Value:$195.6M
BLACKROCK FUND ADVISORS
Shares:4.38M
Value:$171.44M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:3.39M
Value:$132.68M
Summary
Showing Top 3 of 205